Checkpoint Therapeutics Inc. is planning an underwritten public offering of its common stock.
The New York-based immuno-oncology biopharmaceutical company expects to grant the underwriters an overallotment option to buy up to an additional 15% of the shares offered.
Checkpoint plans to use the net proceeds for developing its product candidates, the potential in-license, acquisition, development and commercialization of other pharmaceutical products and for general corporate purposes.
National Securities Corp. is acting as sole book-running manager, while Lake Street Capital Markets LLC is acting as an independent underwriter for the offering.
